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Abstract
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder 
characterised by the combined occurrence of parathyroid, pituitary and pancreatic 
islet tumours, and is due to mutations of the MEN1 gene, which encodes the tumour 
suppressor protein menin. Menin has multiple roles in genome stability, transcription, 
cell division and proliferation, but its mechanistic roles in tumourigenesis remain to be 
fully elucidated. miRNAs are non-coding single-stranded RNAs that post-transcriptionally 
regulate gene expression and have been associated with tumour development, although 
the contribution of miRNAs to MEN1-associated tumourigenesis and their relationship 
with menin expression are not fully understood. Alterations in miRNA expression, 
including downregulation of three putative ‘tumour suppressor’ miRNAs, miR-15a, 
miR-16-1 and let-7a, have been reported in several tumour types including non-MEN1 
pituitary adenomas. We have therefore investigated the expression of miR-15a, miR-16-1 
and let-7a in pituitary tumours that developed after 12 months of age in female mice 
with heterozygous knockout of the Men1 gene (Men1+/− mice). The miRNAs miR-15a, 
miR-16-1 and let-7a were significantly downregulated in pituitary tumours (by 2.3-fold, 
P < 0.05; 2.1-fold P < 0.01 and 1.6-fold P < 0.05, respectively) of Men1+/− mice, compared 
to normal WT pituitaries. miR-15a and miR-16-1 expression inversely correlated 
with expression of cyclin D1, a known pro-tumourigenic target of these miRNAs, and 
knockdown of menin in a human cancer cell line (HeLa), and AtT20 mouse pituitary cell 
line resulted in significantly decreased expression of miR-15a (P < 0.05), indicating that 
the decrease in miR-15a may be a direct result of lost menin expression.
Introduction
Multiple endocrine neoplasia type 1 (MEN1) is an 
autosomal dominant disorder characterised by the 
combined occurrence of parathyroid, pituitary and 
pancreatic islet tumours (Pieterman et  al. 2009, Goudet 
et al. 2010, Thakker et al. 2012, Frost et al. 2018). MEN1 is 
due to mutations of the MEN1 gene, which encodes the 
tumour suppressor protein menin (Chandrasekharappa 
et al. 1997, Concolino et al. 2016, Lemos & Thakker 2008, 
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Lemmens et al. 1997). Loss of menin expression is observed 
in the majority of MEN1-associated tumours, in keeping 
with Knudson’s two-hit model of inherited tumourigenesis 
(Chandrasekharappa et  al. 1997, Concolino et  al. 2016, 
Lemos & Thakker 2008, Lemmens et  al. 1997). Menin 
is involved in a diverse range of cellular processes 
including: transcriptional regulation, genome stability, 
cell division and proliferation (Thakker et al. 2012, Frost 
et al. 2018). However, the mechanisms by which menin 
loss results in tumourigenesis are not fully understood. 
One mechanism that is likely to be implicated involves 
miRNAs, which have been reported to have roles in the 
development of a large number of other tumour types 
(Filipowicz et al. 2008, Stefani & Slack 2008). Moreover, 
menin has been reported to regulate the expression of 
miRNAs (Luzi et  al. 2012a,b, Wang et  al. 2013, Gurung 
et  al. 2014, Li et  al. 2014, Ouyang et  al. 2015, Ehrlich 
et al. 2017, Hou et al. 2017), which are short, non-coding, 
single-stranded RNAs that post-transcriptionally regulate 
gene expression, predominantly by imperfect base pairing 
to the 3′ untranslated region (UTR) of target mRNA 
sequences (Filipowicz et al. 2008, Stefani & Slack 2008). 
The importance of miRNAs has been illustrated by their 
ability to influence a wide spectrum of cellular processes 
including proliferation, apoptosis and differentiation, in 
a tissue-specific manner and many miRNAs have been 
implicated in tumour development through the ability to 
influence the expression of a diverse set of target genes, 
including tumour suppressors and oncogenes (Peng & 
Croce 2016).
The role of miRNAs in pituitary tumourigenesis 
has been investigated by microarray-based profiling 
studies, which have revealed changes in their expression 
(Wierinckx et  al. 2017). For example, sporadic human 
pituitary tumours have been reported to have altered 
expression of multiple miRNAs, when compared to 
normal pituitary tissue (Bottoni et al. 2005, 2007, Amaral 
et al. 2009, Qian et al. 2009, D’Angelo et al. 2012, Palmieri 
et al. 2012). The functional significance of such changes in 
miRNA expression in endocrine tumourigenesis, especially 
in relation to MEN1-associated pituitary tumours remains 
unknown. It has however been demonstrated that 
the putative tumour suppressor miRNAs miR-15a, 
miR-16-1 and let-7 are downregulated in non-functioning 
adenomas, prolactinomas, somatotrophinomas and 
corticotrophinomas and that loss of miR-15a and miR-16-1 
correlates with increased tumour diameter, while loss 
of let-7 expression is correlated with increased tumour 
grade (Bottoni et al. 2005, 2007, Amaral et al. 2009, Qian 
et  al. 2009, D’Angelo et  al. 2012, Palmieri et  al. 2012). 
The specific genetic targets of these miRNAs in pituitary 
neuroendocrine tumours have not been elucidated, 
but studies in chronic lymphocytic leukaemia (CLL) 
have shown that loss of miR-15a and miR-16-1, which 
co-occur as a cluster, allows overexpression of BCL2, while 
investigations in prostate and non-small-cell lung cancer 
have reported that downregulation of miR-15a and 
miR-16-1 results in increased cyclin D1 (CCND1) expression, 
with each contributing to tumour formation (Cimmino 
et al. 2005, Bonci et al. 2008, Calin et al. 2008, Bandi et al. 
2009, Croce 2009, Salerno et al. 2009). Similarly, in non-
endocrine tumours members of the let-7a family have 
been shown to target the oncogenes KRAS, MYC and 
HMGA2 (Johnson et al. 2005, Mayr et al. 2007, Kumar et al. 
2008) in a tumour-specific manner. In addition, menin 
has been reported to directly regulate the expression of 
miRNA genes via its role as a transcriptional regulator 
or through miRNA processing (Luzi et al. 2012a,b, Wang 
et al. 2013, Gurung et al. 2014, Li et al. 2014, Ouyang et al. 
2015, Ehrlich et al. 2017, Hou et al. 2017), although the 
role of miRNAs in MEN1-associated tumours remains to 
be established. Therefore to determine if the reported 
downregulation of miR-15a, miR-16-1 and let-7a in 
pituitary tumours is a result of loss of menin expression, 
we investigated the role of menin in the regulation of 
miR-15a, miR-16-1 and let-7a, using a previously reported 
murine model of MEN1 (Harding et al. 2009), the mouse 
pituitary cell line AtT20 and a human cell-based assay 
that utilised the human cervical adenocarcinoma (HeLa) 
cell line.
Materials and methods
Generation of Men1+/− mice
Animal studies were approved by the University of Oxford 
Ethical Review Committee and were licensed under the 
Animal (Scientific Procedures) Act 1986, issued by the 
United Kingdom Government Home Office Department 
(PPL30/2914). A conventional Men1-knockout model 
generated by targeted deletion of exons 1 and 2 of the 
Men1 allele was used (Harding et  al. 2009, Lemos et  al. 
2009). The Men1+/− mice have been reported to develop 
parathyroid, pancreatic islet, anterior pituitary, adrenal 
cortical and gonadal tumours (Harding et al. 2009). This 
model was selected for investigation as greater than 40% 
of female mice (over the age of 12  months) develop 
discrete anterior pituitary tumours readily identifiable 
at autopsy (Harding et  al. 2009). Genotypes of mice 
This work is licensed under a Creative Commons 
Attribution 4.0 Unported License.https://doi.org/10.1530/JOE-18-0278
https://joe.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd.
Printed in Great Britain Downloaded from Bioscientifica.com at 12/13/2018 12:25:01PM
via University of Dundee
43
Research
K E Lines, P J Newey et al. miR-15a/miR-16-1 expression 
in MEN1 NETs
240:1Journal of 
Endocrinology
were determined by PCR analysis using DNA extracted 
from ear biopsies and Men1 gene-specific primers, as 
previously reported (Lemos et  al. 2009). Primers Men1F 
(5′-TAGATGTAGCTGGATGGTGATGG-3′) and Men1R 
(5′-ATGAAGCTGAGGAGATGATGTAG-3′) yielded a 582 
base-pair WT fragment and primers Men1F and NeoR 
(5′-GCTGACCGCTTCCTCGTG-3′) yielded a 809 base-pair 
mutant fragment (Supplementary Fig.  1A, see section 
on supplementary data given at the end of this article). 
The mice were fed a standard diet (Rat and Mouse No. 1 
expanded diet, Special Diet Services Ltd.), provided with 
water ad libitum, and weighed regularly. Pituitaries were 
isolated from five tumour-bearing female Men1+/− and 
five female WT (Men1+/+) mice, aged over 12 months and 
both maintained on a C57BL/6 background, for miRNA 
analysis. The study was limited to female mice because 
<5% of Men1+/− males develop pituitary tumours (Harding 
et al. 2009). The pituitary tumours from Men1+/− mice in 
this cohort, as previously reported (Harding et al. 2009), 
had loss of menin expression, compared to WT pituitaries 
isolated from Men1+/+ mice (Supplementary Fig. 1B). Both 
pituitary tumours and WT pituitaries expressed prolactin 
(Supplementary Fig. 1B).
Cell lines
Human MEN1-associated pituitary tumour cell lines or 
normal human pituitary cell lines are not available, and 
we therefore used the HeLa cell line to investigate the 
relationship between miR-15a, miR-16-1, cyclin D1 and 
Men1, as these cells express both miR-15a and miR-16-1, 
as well as menin and cyclin D1 (Supplementary Fig. 2), 
and a previous study has mapped the genomic binding 
sites of menin in these cells (Scacheri et al. 2006). HeLa 
cells (#CCL-2) and AtT20 cells (#CCL-89) were purchased 
from ATCC and used up to passage eight from the original 
stock. Both cell lines were maintained in Dulbecco’s 
Modified Eagle medium (DMEM), supplemented with 
100 U/mL penicillin, 100 μg/mL streptomycin, 2 mM 
l-glutamine and 10% heat-inactivated foetal calf serum at 
37°C, 5% CO2 and 95% humidity.
Antagomir transfections
MicroRNA inhibitors (‘antagomirs’) to miR-15a and 
miR-16-1, as well as the control antagomir miR-1, were 
custom designed and purchased from Thermo Scientific 
(Table  1). Antagomirs are engineered oligonucleotides 
that competitively bind to a target miRNA and inhibit 
their activity. HeLa cells were seeded in six-well plates and 
transfected with 100 nM antagomirs diluted in serum free 
DMEM, using Dharmafect 1 transfection reagent (Thermo 
Scientific). Forty-eight hours post transfection cells were 
harvested for further analysis.
siRNA transfection
Cells were seeded in six-well plates and transfected with 
25 nM of either control, non-targeting (NT) siRNA or a 
species specific ON-TARGETplus SMARTpool of siRNAs 
against MEN1, using Dharmafect 1 transfection reagent 
(all Thermo Scientific) prepared in serum-free DMEM. 
After addition of siRNA, cells were incubated for 48 h and 
miRNA or protein harvested for further analysis.
Quantitative reverse-transcriptase PCR (qRT-PCR)
Total RNA, including the miRNA fraction, was extracted 
from both mouse tissues and cell lines using the 
mirVana miRNA Isolation Kit (Ambion) according to 
the manufacturer’s instructions, and as previously 
described (Ma et al. 2007). RNA quality was determined 
by a NanoDrop ND-1000 Spectrophotometer (NanoDrop 
Technologies) and agarose gel electrophoresis. Up to 
1 µg of total RNA was subsequently converted to cDNA 
using the miScript RT II kit (Qiagen), with HiFlex 
buffer (Qiagen) and qRT-PCR reactions were performed 
using the miScript SYBR green kit, according to the 
manufacturer’s instructions, on a Rotor-Gene Q Cycler 
(Qiagen). Human and mouse-specific miScript primer 
assays (Qiagen) were purchased for all miRNAs, and 
human and mouse specific QuantiTect primer assays 
(Qiagen) for all mRNAs. For all miRNA experiments data 
was normalised to the small nucleolar reference RNAs 
RNU6B and SNORD95, and for all mRNA experiments, 
data were normalised to the control mRNA GAPDH. The 
relative expression of target cDNA in all qRT-PCR studies 
was determined using the Pfaffl method, as previously 
described (Lines et al. 2017).
Western blot
Cell lines and mouse pituitary tissues were lysed in 
NP40 lysis buffer: 250 mM NaCl, Tris 50 mM (pH 8.0), 
5 mM EDTA, 0.5% NP-40 (v/v) and 2× Protease inhibitor 
tablets (Roche). Pituitary tissue samples were removed 
from −80°C storage immediately prior to use and 
homogenised in an appropriate volume of ice-cold NP40 
lysis buffer. Cell lines were washed in PBS and each 
well lysed in 500 μL ice-cold NP40 buffer. Samples were 
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incubated on ice for 10 min, centrifuged for 10 min at 
96,000 g and the supernatant removed for analysis. Lysates 
were prepared in 5× Laemmli loading dye: 45 mmol/L 
Tris (pH 6.8), 10% glycerol, 1% SDS, 50 mmol/L DTT, 
0.01% bromophenol blue, boiled at 95°C for 5 min and 
resolved using SDS-PAGE gel electrophoresis. Samples 
were transferred onto PVDF membrane (PerkinElmer), 
blocked in 5% Marvel (powdered-milk) in TBS-T and 
incubated with 1:100 rabbit anti-cyclin D1 antibody 
(AbCam), 1:1000 rabbit anti-menin antibody (Bethyl 
Laboratories) or 1:1000 rabbit anti-α-tubulin (AbCam) 
at 4°C overnight. Membranes were subsequently 
incubated with appropriate HRP-conjugated secondary 
antibodies and visualised using ECL Western blotting 
substrate (BioRad) on a BioRad Chemidoc XRS+ system 
and densitometric analysis performed using Image J, as 
previously described (Lines et al. 2017).
Histology and immunohistochemistry
Pituitary tissues were dissected from mice, fixed with 
4% paraformaldehyde, embedded in paraffin, and 4 μM 
sections dewaxed and hydrated for staining, as described 
(Lines et al. 2017). Sections were stained with haematoxylin 
and eosin, as previously described (Walls et al. 2016) or 
used for immunohistochemical staining, in which heat-
mediated antigen retrieval was performed in citrate buffer 
and blocking in 10% donkey serum, before primary 
antibody incubation. Primary antibodies included rabbit 
anti-menin (ab2605 (AbCam)), and rabbit anti-prolactin 
(National Hormone and Pituitary Programme (NHPP)). 
The secondary antibody was horseradish peroxidase-
conjugated goat anti-rabbit (Dako), visualised with a 
peroxidase/3,3′-diaminobenzidine Envision detection 
system (Dako). Nuclear counterstaining was performed 
with haematoxylin QS (Vector Laboratories). Sections were 
viewed by light or fluorescent microscopy using an Eclipse 
E400 microscope (Nikon), utilising a DXM1200Cdigital 
camera and NIS-Elements BR 2.30 software (both Nikon), 
as described (Lines et al. 2017).
Statistical analysis
Data were analysed using Students t-test or one-way 
ANOVA using a Bonferroni correction for multiple 
comparisons, as previously described (Walls et  al. 2012, 
Gorvin et al. 2013, Lines et al. 2017).
Results
miR-15a, miR-16-1 and let-7a expression are reduced 
in Men1+/− mouse pituitary tumours
Quantitative RT-PCR analysis of pituitary tumours isolated 
from Men1+/− mice or normal pituitary tissue isolated from 
WT mice, revealed the pituitary tumours, when compared 
to normal pituitaries, to have a significant decrease in the 
expression of miR-15a (2.3-fold, P < 0.05), miR-16-1 (2.1-
fold P < 0.01) and let-7a (1.6-fold P < 0.05) (Fig. 1A, B and 
C). This observed downregulation of miR-15a, miR16-1 
and let-7a in the Men1+/− pituitary tumours was consistent 
with their reported reduced expressions in human 
pituitary tumours (Bottoni et al. 2005, 2007, Amaral et al. 
2009, Qian et  al. 2009, D’Angelo et  al. 2012, Palmieri 
et al. 2012). miR-15a and miR-16-1 are transcribed from 
the same polycistronic cluster, and an analysis of these 
miRNAs in the ten individual samples, demonstrated a 
significant positive correlation between the two miRNAs, 
consistent with co-transcription (R2 = 0.77; P < 0.001, 
Fig. 1D).
Decreased expression of miR-15a and miR-16-1 
negatively correlates with CCND1 mRNA expression 
in Men1+/− mouse pituitary tumours
CCND1 is reported to be regulated by miR-15a/miR-16-1 
in prostate and non-small-cell lung cancer (Cimmino 
et al. 2005, Bonci et al. 2008, Calin et al. 2008, Bandi et al. 
2009, Croce 2009, Salerno et al. 2009), and we therefore 
examined CCND1 expression in the pituitary of the 
Men1+/− mice that had reduced expression of miR-15a and 
Table 1 Antagomir sequence.
Antagomir Sequence
miR-15a 5′-mC(*)mA(*)mCmAmAmAmCmCmAmUmUmAmUmGmUmGmCmUmG(*)mC(*)mU(*)mA(*)-Chol-3′
miR-16-1 5′-mC(*)mG(*)mCmCmAmAmUmAmUmUmUmAmCmGmUmGmCmUmG(*)mC(*)mU(*)mA(*)-Chol-3′
miR-1 (Control) 5′-mA(*)mU(*)mAmCmAmUmAmCmUmUmCmUmUmUmAmCmAmUmU(*)mC(*)mC(*)mA(*)-Chol-3′
Specific mature mRNA binding oligonucleotide sequences, antagomirs, were designed to inhibit miR-15a and miR-16-1 activity by preventing the 
interaction of the miRNA with its mRNA seed sequence. A control miRNA, miR-1, was also designed. All antagomirs contain internal modifications to 
protect them from RNase-mediated degradation.
(*): Indicates a phosphorothioate linkage; ‘m’ indicates 2′-O-methyl modified nucleotides; ‘Chol’ represents a cholesterol group.
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miR-16-1 (Fig.  1A, B and C). This revealed a significant 
increase in CCND1 mRNA levels in Men1+/− pituitary 
tumours (n = 5), when compared to normal pituitaries 
(n = 5) from WT mice (2.6-fold, P < 0.0005, Fig. 2A). These 
findings were confirmed by Western blot (Fig.  2B) and 
densitometry analyses (Fig.  2C), which revealed that 
expression of the cyclin D1 protein was significantly 
higher (by 4.6-fold to 8.7-fold, P < 0.05–0.005) in 
the pituitary tumours than in those of the normal 
pituitaries. Moreover, there was a significant inverse 
correlation between the levels of CCND1 mRNA and 
both miR-15a (Fig. 2D, R2 = 0.81; P < 0.0005), and miR-16-1 
(Fig.  2E, R2 = 0.78, P < 0.001), thereby suggesting that 
CCND1 mRNA may be under the direct regulation of 
miR-15a and miR-16-1. Analysis of the expression of a 
putative let-7a mRNA target, KRAS revealed significantly 
increased expression of KRAS (by 1.5 fold, P < 0.005, 
Supplementary Fig.  3A), in the pituitary tumours of 
Men1+/− mice, when compared to normal pituitaries of 
Men1+/+ mice, although a significant inverse correlation 
was not observed between the expression of KRAS and 
let-7a (Supplementary Fig. 3B).
Cyclin D1 expression is directly regulated by miR-15a 
and miR-16-1
To further analyse the relationship between these miRNAs 
and cyclin D1, we altered the levels of miR-15a and 
miR-16-1 in vitro by transfecting HeLa cells with antagomirs 
that inhibited miR-15a and miR-16-1. Treatment with the 
miR-15a antagomir significantly decreased expression of 
miR-15a (14-fold (P < 0.05)), but not miR-16-1 (Fig.  3A), 
and treatment with the miR-16-1 antagomir significantly 
decreased miR-16-1 expression (12-fold (P < 0.005), but 
not miR-15a (Fig. 3B). miR-15a and miR-16-1 antagomir 
treatment also led to significant increases in cyclin D1 
expression (3.1-fold (P < 0.05) and 3.8-fold (P < 0.005), 
respectively, Fig. 3C and D). Simultaneous transfection of 
HeLa cells with antagomirs to both miR-15a and miR-16-1 
resulted in similar decreases in expression to that observed 
with single antagomir transfection (both P < 0.05, Fig. 3A 
and B), although the increase in cyclin D1 expression 
was lower in the co-transfected cells (2.4-fold, P < 0.05, 
Fig. 3C and D).
Menin regulates the expression of miR-15a
Menin has been reported to regulate, and to be regulated by 
miRNAs, including via feedback loops (Luzi et al. 2012a,b, 
Wang et al. 2013, 2014, Caplin et al. 2014, Gurung et al. 
2014, Li et al. 2014, Vijayaraghavan et al. 2014, Lu et al. 
2015, Ouyang et al. 2015, Ehrlich et al. 2017, Hou et al. 
2017). To determine if there was a feedback loop present 
between menin and miR-15a/miR-16-1, we examined the 
effects of antagomir-induced inhibition of miR-15a or 
miR-16-1 on menin expression in HeLa cells using qRT-
PCR and Western blot analyses. Antagomirs to miR-15a 
and miR-16-1 did not alter expression of the MEN1 gene or 
menin (Fig. 4A and B), indicating that menin expression 
is not directly regulated by miR-15a or miR-16-1. To 
assess the possible role of menin in regulating miR-15a 
or miR-16-1 expression, menin knockdown experiments 
were performed in human HeLa cells, and in the mouse 
pituitary cell line AtT20, and miR-15a and miR-16-1 levels 
analysed using qRT-PCR. Knockdown of menin in HeLa 
and AtT20 cells, which was confirmed at both the mRNA 
(both P < 0.0005, Fig.  4C) and protein levels (Fig.  4D), 
resulted in a significant decrease in miR-15a expression 
(P < 0.005 and P < 0.05 respectively, Fig.  4E) but not of 
miR-16-1 (Fig. 4F). miR-15a and miR-16-1 expression are 
reported to be under the control of a promoter of their 
host gene, DLEU2 (Lerner et al. 2009), but our analysis of 
DLEU2 expression following menin knockdown in HeLa 
Figure 1
miR-15a, miR-16-1 and let-7a expression in pituitary tumours developing 
in Men1+/− mice. The expression of miR-15a, miR-16-1 and let-7a was 
compared in five pituitary tumours (closed circles) from Men1+/− female 
mice to five normal pituitaries (open circles) from age- and sex-matched 
WT Men1+/+ control mice, using qRT-PCR. The mean and standard error of 
the mean are shown and samples were normalised to WT, which was set 
at 1. Expression of miR-15a (A), miR-16-1 (B) and let-7a (C) were each 
significantly decreased in pituitary tumour samples from Men1+/− mice 
compared to normal pituitary samples from Men1+/+ mice; *P < 0.05, 
**P < 0.005. A significant positive correlation was also observed between 
the relative expression of miR-15a and miR-16-1 in the ten Men1-
associated pituitary samples (tumour (closed circles) n = 5, and normal 
(open circles) n = 5) consistent with transcription from the same 
polycistronic cluster (D, R2 = 0.77, P < 0.001).
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and AtT20 cells revealed that there were no alterations in 
DLEU2 expression (Supplementary Fig.  4). This finding, 
which is consistent with the observation that the 
promoter region of DLEU2 does not contain a menin-
binding site (Scacheri et  al. 2006), indicates that menin 
does not appear to regulate the expression of miR-15a by 
direct binding to the DLEU2 promoter, but instead may 
influence expression via alternate mechanisms.
Discussion
Our study has revealed that (1) the expression of 
the microRNAs miR-15a, miR-16-1 and let-7a are 
downregulated in pituitary tumours that develop in a 
Men1+/− mouse model; (2) there is a significant positive 
correlation between miR-15a and miR-16-1 expression; 
(3) the decreased miR-15a and miR-16-1 expression is 
associated with increased cyclin D1 expression and (4) 
that loss of menin expression is associated with a decrease 
in miR-15a expression.
The decreased expression of miR-15a, miR-16-1 
and let7a in the pituitary tumours of Men1+/− mice is in 
agreement with the reported down regulation of these 
miRNAs in human pituitary tumours (Bottoni et  al. 
2005, 2007, Amaral et al. 2009). In addition, the positive 
correlation between miR-15a and miR-16-1 in the Men1+/− 
mouse pituitary tumours (Fig.  1) indicates that these 
miRNAs are likely transcribed as a polycistronic cluster, 
under the control of the same promoter elements, as 
reported for these miRNAs in patients with chronic 
lymphocytic leukaemia (CLL) (Calin et al. 2008). Moreover, 
in humans, the miR-15a-miR-16-1 cluster is thought 
to act as a tumour suppressor and its chromosomal 
location (13q14) is a site of frequent allelic disruption 
Figure 2
Correlation of miR-15a and miR-16-1 with CCND1. Analysis of five Men1+/− pituitary tumours (closed circles) and five WT pituitary samples (open circles) by 
qRT-PCR demonstrated a significant increase in expression of CCND1, a known target of miR-15a and miR-16-1, in the tumour samples (A, ***P < 0.0001). 
Cyclin D1 protein expression, encoded by CCND1, was evaluated in four tumours from Men1+/− mice and four normal pituitaries from WT mice (Men1+/+), 
using Western blot analyses. All four pituitary tumours expressed cyclin D1, whereas cyclin D1 was not detectable in the normal pituitary samples (B). 
Densitometry analysis of four Western blots confirmed that cyclin D1 expression is significantly higher in the four pituitary tumours (T1–T4 and filled 
bars) from Men1+/− mice compared to normal (N1–N4 and open bars) pituitaries from WT (Men1+/+ mice) (C, *P < 0.05, **P < 0.005). All values were 
normalised to α-tubulin expression. A significant negative correlation was observed in the relative expression of both miR-15a (D) and miR-16-1 (E) 
compared to CCND1 (D, R2 = 0.81, P < 0.0005 and E, R2 = 0.78, P < 0.001, respectively).
Figure 3
miR-15a and miR-16-1 antagomir treatment increases cyclin D1 
expression in human HeLa cells. Inhibition of miR-15a and miR-16-1 
binding to their target mRNAs was performed using antagomir 
transfections in HeLa cells. miRNA-15a levels were significantly reduced 
when HeLa cells were transfected with antagomirs targeting either 
miR-15a alone or against both miR-15a and miR-16-1 (*P < 0.05) (A).  
A significant decrease in miR-16-1 levels was also seen when cells were 
transfected with antagomirs targeting miR-16-1 alone or both miR-15a 
and miR-16-1 (*P < 0.05 and ** P < 0.01) (B). Forty-eight hours following 
antagomir transfection the levels of cyclin D1 were assessed using 
Western blot analyses, and α-tubulin was used as a loading control (C). 
Densitometry analysis of the Western blots (n = 4) revealed that cyclin D1 
expression was significantly increased following transfection with 
antagomirs targeting either miR-15a, miR-16-1 alone or in combination 
(*P < 0.05, **P < 0.005) (D). UT, untransfected.
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or loss in several tumours including CLL, prostate 
cancer and pituitary tumours where its loss is associated 
with aggressive features (Pei et  al. 1995, Hyytinen et  al. 
1999, Dong et  al. 2001, Calin et  al. 2002, 2008). These 
observations support a role for miR-15a and miR-16-1 in 
the aetiology of MEN1-associated pituitary tumours.
The observation of increased cyclin D1 protein 
expression in association with down regulation of miR-15a 
and miR-16-1 in pituitary tumours from Men1+/− mice 
(Fig.  2), suggests that cyclin D1 is a putative target of 
miR-15a and miR-16-1 in these Men1-associated pituitary 
tumours. In addition, transfection of HeLa cells with 
specific antagomirs to miR-15a and miR-16-1 significantly 
increased cyclin D1 expression (Fig. 3), thereby confirming 
that cyclin D1 is a likely target of these miRNAs, and this 
is in agreement with previous human and mouse studies 
which have reported that cyclin D1 overexpression occurs 
in a significant proportion of human sporadic pituitary 
tumours (Gazioglu et  al. 2007) and that miR-15a and 
miR-16-1 can directly regulate cyclin D1 expression 
in osteosarcoma and CLL (Salerno et al. 2009, Cai et al. 
2012), and that the miR-15a and miR-16-1-binding sites 
in the 3′ UTR of cyclin D1 are highly conserved across 
species (Deshpande et al. 2009). This negative correlation 
between the decreased expression of both miR-15a and 
miR-16-1 and the increased expression of Ccnd1 in Men1-
associated pituitary tumours (Fig. 2) was not observed to 
occur between Kras and let-7a (Supplementary Fig.  3). 
Previous studies of laryngeal and lung cancers have 
reported that let-7a can regulate the expression of KRAS, 
and that menin is involved in let-7a miRNA processing 
(Johnson et al. 2005, Long et al. 2009, He et al. 2010, Oh 
et al. 2010, Guan et al. 2011, Wang et al. 2013, Gurung 
et al. 2014). However, our findings suggest that let-7a does 
not regulate Kras in pituitary tumours of Men1+/− mice and 
that it may act via alternative targets.
Menin was found to cause a decrease in miR-15a 
levels in the pituitary tumours of the Men1+/− mice, 
and this is similar to reports showing that menin can 
negatively regulate the expression of miR-26a and 
miR-29b (Luzi et al. 2012a, Ouyang et al. 2015). In addition, 
menin has been reported to form a negative feedback 
loop with miR-24-1, which can mimic the second ‘hit’ of 
MEN1 i.e. loss of the second MEN1 allele (Luzi et al. 2012b) 
and that miRNAs miR-421, miR-24, miR-802, miR-17 and 
miR-762 can all regulate menin expression (Caplin et al. 
2014, Vijayaraghavan et  al. 2014, Wang et  al. 2014, Lu 
et al. 2015, Ehrlich et al. 2017, Hou et al. 2017). However, 
our results, which revealed that antagomirs of miR-15a or 
miR-16-1 did not affect menin expression (Fig. 4), do not 
support the existence of a feedback loop between these 
miRNAs and menin.
We demonstrate that in vitro knockdown of menin in 
HeLa and AtT20 cells significantly reduced the expression 
of miR-15a, but not miR-16-1 (Fig.  4). In addition, 
expression of DLEU2 which is regulated under the 
same promoter as the miR-15a-miR-16-1 cluster (Lerner 
et  al. 2009) was not altered after menin knockdown 
(Supplementary Fig.  4). It has previously been reported 
that in HEK293 cells menin can bind to the arsenite 
resistance protein (ARS2), which is involved in stabilising 
capped primary miRNA transcripts and delivering them 
to the primary miRNA processing complex (Gurung 
et  al. 2014). Furthermore, loss of menin resulted in 
reduced levels of mature let-7a miRNA, but did not affect 
primary miRNA levels (Gurung et  al. 2014). Therefore, 
we hypothesise that the loss of menin in the pituitary 
tumours and cell lines in our study disrupts the activity 
of ARS2, leading to dysregulation of miR-15a-miR-16-1 
Figure 4
Relationship between miR-15a/miR-16-1 and menin in HeLa and AtT20 
cells. Significant differences were not observed in the levels of Men1 or 
menin expression after antagomir treatment of HeLa cells, evaluated by 
qRT-PCR (A) and Western blot (B), respectively. Use of MEN1-specific siRNA 
in HeLa and AtT20 cells decreased expression of MEN1 (C) (assessed by 
qRT-PCR, ***P < 0.0005) and menin (D) (assessed by Western blot 
analysis). The decreased expression of MEN1 and menin, caused by the 
specific MEN1 siRNA, resulted in a significant decrease in the expression 
of miR-15a in both HeLa and AtT20 cells (E, **P < 0.005; *P < 0.05), but not 
in miR-16-1 expression (F). NT, non-targeting siRNA; UT, untransfected.
This work is licensed under a Creative Commons 
Attribution 4.0 Unported License.https://doi.org/10.1530/JOE-18-0278
https://joe.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd.
Printed in Great Britain Downloaded from Bioscientifica.com at 12/13/2018 12:25:01PM
via University of Dundee
48miR-15a/miR-16-1 expression 
in MEN1 NETs
K E Lines, P J Newey et al. 240:1Journal of 
Endocrinology
miRNA processing. However, in the tumours from menin 
null mice we observed a significant decrease in both 
miR-15a and miR-16-1, expression (Fig. 1); but, in the in vitro 
menin knockdown studies, we only observed a decrease 
in miR-15a (Fig. 4). There are two possible explanations 
for this: first in the in vitro studies, we did not observe 
complete menin loss as is seen in the Men1+/− mouse 
tumours, and therefore the residual menin expression may 
be attenuating the phenotype or second the menin-null 
tumours may accumulate additional mutations that can 
further alter miRNA expression, potentially by modifying 
the allelic imbalance of miR-15a-miR-16-1 expression, as 
reported in CLL (Veronese et al. 2015). These studies in CLL 
have reported that expression of miR-15a and miR-16-1 
shows allelic imbalance, with transcription of this cluster 
being simultaneously regulated by RNA polymerase (RP) 
II and RPIII mechanisms (Veronese et  al. 2015). Thus, 
miR-15a-miR-16-1 could be transcribed by RPII as a capped 
primary miRNA sequence or after splicing as an uncapped 
transcript by RPIII and as ARS2 is involved in stabilising 
capped primary miRNA transcripts, the menin-ARS2 
interaction would only be important for RPII-mediated 
transcription (Lee et al. 2004, Veronese et al. 2015).
In conclusion, we demonstrate that miR-15a and 
miR-16-1 are both downregulated in pituitary tumours of 
Men1+/− mice and that this decrease in expression correlates 
with an increase in cyclin D1 expression. Moreover, in 
human cells, inhibition of miR-15a and miR-16-1 binding 
to mRNA using antagomirs significantly increases cyclin 
D1 expression, and this may be due to altered processing 
of miR-15a by menin, as our menin-knockout studies 
revealed a significant decrease in miR-15a.
Supplementary data
This is linked to the online version of the paper at https://doi.org/10.1530/
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